Moderna, Inc. $MRNA Stock: Oppenheimer & Co. Inc. Raises Position

Oppenheimer & Co. Inc. increased its position in Moderna, Inc. (NASDAQ:MRNA) by 79.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,824 shares of the company’s stock after buying an additional 7,007 shares during the period. Oppenheimer & Co. Inc.’s holdings in Moderna were worth $3,047,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Park Avenue Securities LLC purchased a new position in shares of Moderna during the 3rd quarter worth $864,000. Apollon Wealth Management LLC grew its position in shares of Moderna by 13.6% in the third quarter. Apollon Wealth Management LLC now owns 5,973 shares of the company’s stock valued at $1,150,000 after purchasing an additional 713 shares during the period. Aries Wealth Management purchased a new stake in shares of Moderna in the third quarter valued at $385,000. Kingswood Wealth Advisors LLC purchased a new stake in shares of Moderna in the third quarter valued at $348,000. Finally, Sigma Planning Corp acquired a new position in Moderna in the third quarter valued at $287,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MRNA. Citigroup reiterated a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. Morgan Stanley lifted their price target on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Bank of America upped their price objective on shares of Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Finally, Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $107.10.

Moderna Trading Down 0.5%

MRNA stock opened at $221.72 on Friday. The company has a market cap of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.09. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $182.49 and a 200-day simple moving average of $86.52. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $254.48.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the firm earned ($2.13) earnings per share. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts expect that Moderna, Inc. will post -6.11 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 197,251 shares of company stock worth $33,875,904 over the last three months. 10.80% of the stock is owned by insiders.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.